CA3188752A1 - Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection - Google Patents
Benzodiazepine derivatives useful in treating a respiratory syncytial virus infectionInfo
- Publication number
- CA3188752A1 CA3188752A1 CA3188752A CA3188752A CA3188752A1 CA 3188752 A1 CA3188752 A1 CA 3188752A1 CA 3188752 A CA3188752 A CA 3188752A CA 3188752 A CA3188752 A CA 3188752A CA 3188752 A1 CA3188752 A1 CA 3188752A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydro
- oxazine
- oxo
- carboxamide
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010409.7A GB202010409D0 (en) | 2020-07-07 | 2020-07-07 | Pharmaceutical compounds |
| GB2010409.7 | 2020-07-07 | ||
| PCT/GB2021/051731 WO2022008911A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188752A1 true CA3188752A1 (en) | 2022-01-13 |
Family
ID=72050502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188752A Pending CA3188752A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230270751A1 (https=) |
| EP (1) | EP4178964A1 (https=) |
| JP (1) | JP7840923B2 (https=) |
| KR (1) | KR20230035597A (https=) |
| CN (1) | CN116075516B (https=) |
| BR (1) | BR112023000142A2 (https=) |
| CA (1) | CA3188752A1 (https=) |
| GB (1) | GB202010409D0 (https=) |
| MX (1) | MX2023000440A (https=) |
| WO (1) | WO2022008911A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202102602D0 (en) | 2021-02-24 | 2021-04-07 | Reviral Ltd | Pharmaceutical compounds |
| WO2024252355A1 (en) | 2023-06-08 | 2024-12-12 | Pfizer Inc. | Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv |
| WO2025120500A1 (en) | 2023-12-06 | 2025-06-12 | Pfizer Inc. | Benzodiazepine compounds as n-protein inhibitors |
| WO2025153942A1 (en) | 2024-01-16 | 2025-07-24 | Pfizer Inc. | Benzodiazepine pyrazolo carboxamides as n-protein inhibitors |
| CN121621343A (zh) * | 2026-02-02 | 2026-03-10 | 云南大学 | 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| NZ538870A (en) | 2002-09-20 | 2007-04-27 | Arrow Therapeutics Ltd | Benzodiazepine derivatives and pharmaceutical compositions containing them |
| GB0406280D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| WO2005090319A1 (en) | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| GB201506448D0 (en) | 2015-04-16 | 2015-06-03 | Univ Durham | An antimicrobial compound |
| DK3324977T3 (da) * | 2015-07-22 | 2022-10-17 | Enanta Pharm Inc | Benzodiazepinderivater som rsv-inhibitorer |
| GB201613942D0 (en) | 2016-08-15 | 2016-09-28 | Univ Of Durham The | An antimicrobial compound |
| US10398706B2 (en) * | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| KR101970214B1 (ko) * | 2017-07-17 | 2019-08-27 | 이화여자대학교 산학협력단 | 유기금속 화합물, 이들의 자기 조립체 및 이를 포함한 종양 진단 또는 치료용 조성물 |
| US10647711B2 (en) * | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915273D0 (en) | 2019-10-22 | 2019-12-04 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202010408D0 (en) | 2020-07-07 | 2020-08-19 | Reviral Ltd | Pharmaceutical compounds |
-
2020
- 2020-07-07 GB GBGB2010409.7A patent/GB202010409D0/en not_active Ceased
-
2021
- 2021-07-07 WO PCT/GB2021/051731 patent/WO2022008911A1/en not_active Ceased
- 2021-07-07 MX MX2023000440A patent/MX2023000440A/es unknown
- 2021-07-07 KR KR1020237003865A patent/KR20230035597A/ko active Pending
- 2021-07-07 EP EP21746095.5A patent/EP4178964A1/en active Pending
- 2021-07-07 JP JP2023501029A patent/JP7840923B2/ja active Active
- 2021-07-07 US US18/004,504 patent/US20230270751A1/en active Pending
- 2021-07-07 CN CN202180053511.8A patent/CN116075516B/zh active Active
- 2021-07-07 BR BR112023000142A patent/BR112023000142A2/pt unknown
- 2021-07-07 CA CA3188752A patent/CA3188752A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7840923B2 (ja) | 2026-04-06 |
| MX2023000440A (es) | 2023-04-13 |
| US20230270751A1 (en) | 2023-08-31 |
| CN116075516A (zh) | 2023-05-05 |
| EP4178964A1 (en) | 2023-05-17 |
| JP2023539985A (ja) | 2023-09-21 |
| BR112023000142A2 (pt) | 2023-01-31 |
| CN116075516B (zh) | 2026-02-03 |
| KR20230035597A (ko) | 2023-03-14 |
| GB202010409D0 (en) | 2020-08-19 |
| WO2022008911A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3188752A1 (en) | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection | |
| AU2018244349B2 (en) | Compounds that inhibit Mcl-1 protein | |
| CA2880251C (en) | Novel heteroaryl and heterocycle compounds, composition and methods thereof | |
| JP6628930B1 (ja) | Ｒｓウイルス（ｒｓｖ）複製の阻害活性を有するピペリジン置換ピラゾロ［１，５−ａ］ピリミジン誘導体 | |
| CA2927252C (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| CA2944475C (en) | Bicyclic-fused heteroaryl or aryl compounds | |
| EP2991977B1 (en) | C-linked heterocycloalkyl substituted pyrimidines and their uses | |
| EP4182313A1 (en) | Kras g12d inhibitors | |
| AU2019237992B2 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| AU2017382029B2 (en) | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors | |
| DK3149008T3 (en) | Specific protein kinase inhibitors | |
| AU2019382504B2 (en) | Cyclic ureas | |
| EP4549438A1 (en) | Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof | |
| CA3047212A1 (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| CA2729045A1 (en) | Pyrimidine compounds, compositions and methods of use | |
| AU2018290511B2 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| AU2007235487A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| CA2800079A1 (en) | Macrocyclic compounds as trk kinase inhibitors | |
| WO2015178955A1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| CA3151232A1 (en) | Pharmaceutical compounds | |
| CA3158169A1 (en) | Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection | |
| AU2018312836A1 (en) | Novel heterocyclic compounds as CDK8/19 inhibitors | |
| AU2021290208B2 (en) | Tricyclic compounds | |
| JP2024545518A (ja) | Ｃｄｋ９阻害剤及びその使用 | |
| CA2963054C (en) | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250616 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250620 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250620 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250827 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250827 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250827 |